Financial Performance - The company reported a net profit of 0 million RMB for the year 2022, with no cash dividends or stock bonuses proposed for distribution [7]. - The company has not yet achieved profitability since its listing, indicating ongoing investment in growth and development [4]. - The company plans to carry forward the undistributed profits to the next fiscal year, reflecting a focus on reinvestment rather than immediate shareholder returns [7]. - The company reported a significant increase in revenue, with a year-over-year growth of 15% in the diagnostics segment [15]. - The company's operating revenue for 2022 reached ¥5,534,792,784.45, representing a year-on-year increase of 94.95% [27]. - The net profit attributable to shareholders for 2022 was ¥1,827,900,394.20, a growth of 53.19% compared to the previous year [27]. - The net cash flow from operating activities increased by 99.37% year-on-year, amounting to ¥1,964,878,081.19, driven by improved collection of receivables [29]. - The total assets of the company at the end of 2022 were ¥4,890,999,989.86, reflecting a 39.77% increase from the previous year [27]. - The basic earnings per share for 2022 were ¥31.18, up 53.14% from ¥20.36 in 2021 [28]. - The company's net assets attributable to shareholders increased by 48.95% to ¥3,778,150,295.65 by the end of 2022 [29]. Research and Development - The company is investing 15% of its revenue into R&D for new technologies and product innovations [15]. - Research and development expenditure as a percentage of operating revenue was 3.36%, a decrease of 0.40 percentage points from the previous year [28]. - The company has a research team of 254 members, with 41.34% holding master's degrees or higher [39]. - R&D investment increased by 74.26% year-on-year, totaling approximately CNY 185.82 million, driven by increased personnel and material costs [63][64]. - The company has developed over 600 products, widely used in infectious disease prevention, clinical testing, large-scale population screening, and reproductive health management [57]. - The company is focusing on POCT technology, which offers rapid, simple, and cost-effective diagnostic solutions, promoting the development of compact and intelligent diagnostic products [55]. Market Expansion and Strategy - The company is expanding its market presence in Europe, targeting a 25% increase in sales in that region over the next year [15]. - The company is actively expanding its market presence and capabilities in response to the growing demand for molecular diagnostics, particularly in the context of the COVID-19 pandemic [52]. - The company is leveraging its proprietary technology platform to maintain a competitive edge in the molecular diagnostics field, particularly in multiplex fluorescent quantitative PCR technology [53]. - The company is implementing a global marketing strategy to target key market areas based on the development of its overseas business [122]. - The company is exploring potential acquisitions to further enhance its product offerings and market presence [133]. Corporate Governance - The audit report issued by Lixin Certified Public Accountants confirmed the financial statements' accuracy and completeness [6]. - The company has not disclosed any special arrangements in corporate governance that would affect the report's integrity [10]. - The board of directors consists of 8 members, including 3 independent directors, ensuring compliance with governance regulations [126]. - The company has established a complete organizational structure, maintaining independence from the controlling shareholder in business, assets, personnel, and finance [127]. - The company has implemented a robust information disclosure management system, ensuring timely and accurate communication with investors [128]. Operational Risks and Challenges - The company has outlined various operational risks and corresponding mitigation strategies in the management discussion section of the report [4]. - The company faces risks of significant performance decline due to reduced demand for COVID-related products and services as the pandemic situation evolves [74]. - The company is at risk of new product development failures due to long R&D cycles (3-5 years) and high uncertainty in the diagnostics market [76]. - The company has a risk of intensified market competition, which could adversely affect its operational performance and profitability [78]. Social Responsibility and ESG - The company emphasizes ESG integration into its operations, focusing on environmental protection and social responsibility, particularly in response to the COVID-19 pandemic [170]. - The company has donated 4.095 million RMB to various charitable causes, including 1 million RMB to Fudan University for a special care fund [181][183]. - The company has not been classified as a key pollutant discharge unit and has met all environmental compliance standards during the reporting period [174]. - The company has implemented measures to ensure zero solid waste discharge during its operations by classifying and properly disposing of hazardous and non-hazardous waste [177]. Employee Management and Compensation - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to RMB 1,178.80 million [142]. - The company has established a comprehensive compensation policy that includes project bonuses and performance bonuses to motivate employees [155]. - The company emphasizes employee training, implementing annual training plans to enhance overall employee skills and capabilities [156]. - The employee composition includes 254 production staff, 422 sales personnel, 254 technical staff, 21 financial staff, and 131 administrative staff [154].

重要内容提示： 2022 年第三季度报告 证券代码：688399 证券简称：硕世生物 江苏硕世生物科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比上 | | 年初至报告期末 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 年同期增减变 | 年初至报告期末 | 比上年同期增减 | | | | 动幅度(%) | | 变动幅度(%) | | 营业收入 | 1,027,556,396.43 | -1.32 | 4,293,492,259.77 | 97. ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2022, representing a year-on-year increase of 20%[1]. - The company reported a revenue of RMB 100 million for the first half of 2022, reflecting a year-on-year growth of 15%[11]. - The company's revenue for the first half of 2022 reached approximately CNY 3.27 billion, representing a growth of 188.88% compared to the same period last year[22]. - The company achieved operating revenue of 3,265.94 million yuan, a year-on-year increase of 188.88%[56]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in Q2 2023, representing a 25% year-over-year growth[114]. - The company provided guidance for Q3 2023, expecting revenue to be between 1.6 billion and 1.7 billion, indicating a growth rate of approximately 20%[114]. - Revenue from COVID-19 nucleic acid testing reagents reached 1,341.67 million yuan, up 210.93% year-on-year[56]. - The net profit attributable to shareholders for the same period was approximately CNY 1.23 billion, an increase of 145.71% year-over-year[22]. - The net profit for the first half of 2022 was ¥1,233,530,249.14, compared to ¥502,032,917.16 in the first half of 2021, reflecting a growth of approximately 145%[161]. User Growth and Market Expansion - User data indicates an increase in active users by 15%, reaching a total of 1.2 million users[1]. - User data indicates an increase in active users by 20% compared to the same period last year, reaching a total of 1 million active users[12]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2023[11]. - Market expansion plans include entering two new provinces, projected to increase market share by 5%[1]. - Market expansion plans include entering three new international markets by Q4 2023, projected to increase overall market share by 10%[114]. Research and Development - The company is investing 30 million RMB in R&D for new technologies aimed at enhancing product efficiency[1]. - Investment in R&D for new technologies has increased by 25%, focusing on in vitro diagnostic reagents and molecular diagnostics[12]. - The total R&D investment for the reporting period reached approximately ¥105.53 million, a significant increase of 187.72% compared to ¥36.68 million in the same period last year[43]. - The company has developed over 600 types of nucleic acid detection products, covering more than 300 disease control centers across various provinces in China[33]. - The company has a strong pipeline of projects, including clinical mass spectrometry detection series and automation intelligent diagnostic devices, with ongoing investments to enhance diagnostic capabilities[46]. - The company has maintained a strong focus on R&D, with total R&D personnel compensation reaching RMB 25.4 million, up from RMB 14.96 million in the previous year[52]. Strategic Initiatives - The company has provided a forward guidance of 10% revenue growth for the second half of 2022[1]. - New product launches are expected to contribute an additional 50 million RMB in revenue by the end of 2022[1]. - A strategic acquisition of a local biotech firm is expected to enhance the company's product portfolio and accelerate growth in the diagnostics sector[12]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 100 million RMB allocated for this purpose[1]. - The company is exploring partnerships with healthcare providers to enhance point-of-care testing capabilities, aiming for a 50% increase in testing volume by 2023[12]. Financial Health and Risks - The company has identified key risks including regulatory changes and market competition, with mitigation strategies in place[1]. - The net cash flow from operating activities increased by 2,558.90% to approximately CNY 851.74 million, driven by improved collection of receivables[22]. - The company reported a rapid increase in accounts receivable, with a net value of CNY 893.74 million, raising concerns about potential bad debts[66]. - The company faces risks from intensified market competition and potential price declines for diagnostic reagents due to regulatory changes[66][67]. - The company acknowledges the unsustainable nature of its recent growth driven by COVID-19 testing products, with future performance uncertain[69]. Corporate Governance and Compliance - No significant non-operational fund occupation by controlling shareholders was reported[1]. - The company has ensured compliance with related party transaction approval procedures and information disclosure obligations[121]. - There were no significant lawsuits or arbitration matters during the reporting period[121]. - The company has committed to minimizing related party transactions and ensuring fair pricing based on market principles[121]. - The company will ensure compliance with legal obligations and commitments made during the issuance and listing process, accepting supervision from regulatory bodies and investors[97]. Shareholder and Dividend Policies - The company plans to prioritize cash dividends, aiming for a minimum of 10% of distributable profits to be distributed in cash if no major investments are planned[106]. - The company plans to maintain a cash dividend ratio of at least 20% if significant capital expenditures occur, ensuring a minimum of 30% of the average annual distributable profits over the last three years are distributed[106]. - The company will communicate with shareholders, especially minority shareholders, to gather feedback on dividend proposals[109]. - The company reported a net profit distribution of CNY -322,410,000.00 for the current period, indicating a loss allocation to shareholders[195]. Operational Efficiency - The management highlighted a strategic focus on digital transformation to improve operational efficiency[1]. - The company aims to reduce operational costs by 15% through efficiency improvements and process optimization initiatives[114]. - The company is committed to continuous innovation and has formed a multidisciplinary R&D team to drive future growth[53]. Product Development and Innovation - The company has launched products in the POCT field, including antigen test kits for influenza, generating revenue[102]. - The introduction of lyophilized reagent technology is expected to reduce transportation costs and extend shelf life, with some products already available in this format[102]. - The company is enhancing its product offerings by integrating advanced technologies like AI and big data for automated testing solutions[102].

Financial Performance - The company's operating revenue for Q1 2022 reached ¥1,521,902,378.62, representing a year-on-year increase of 77.69%[3] - Net profit attributable to shareholders was ¥631,070,096.78, reflecting a growth of 62.90% compared to the same period last year[3] - Basic earnings per share increased to ¥10.77, up 62.93% year-on-year[3] - Operating profit for Q1 2022 was ¥744,064,455.92, up 62.2% from ¥458,996,646.78 in Q1 2021[16] - Net profit attributable to shareholders for Q1 2022 was ¥631,070,096.78, representing a 63.0% increase from ¥387,386,296.05 in Q1 2021[17] - Basic and diluted earnings per share for Q1 2022 were both ¥10.77, compared to ¥6.61 in Q1 2021[17] Cash Flow - The net cash flow from operating activities surged to ¥490,379,975.90, a significant increase of 1,930.58%[3] - Cash flow from operating activities for Q1 2022 was ¥490,379,975.90, a substantial increase from ¥24,149,786.61 in Q1 2021[20] - The company reported a net cash outflow from investing activities of ¥102,147,782.14 in Q1 2022, compared to a net outflow of ¥113,752,091.23 in Q1 2021[21] - The company experienced a net cash inflow from financing activities of ¥26,317,774.10 in Q1 2022, reversing a net outflow of ¥21,278,982.87 in Q1 2021[21] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥4,405,110,023.38, marking a 25.88% increase from the previous year[4] - The company's current assets totaled RMB 3,399,578,863.64, up from RMB 2,538,882,061.99, indicating a rise of about 33.9% year-over-year[11] - The total liabilities of the company amounted to RMB 1,237,590,025.15, compared to RMB 962,893,709.40, which is an increase of approximately 28.5%[13] - The company's equity attributable to shareholders reached RMB 3,167,519,998.23, up from RMB 2,536,449,901.45, representing a growth of about 25%[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,309[9] - The largest shareholder, Shaoxing RunKang Biological Pharmaceutical Equity Investment Partnership, held 26.61% of the shares, totaling 15,600,000 shares[9] Research and Development - Research and development expenses totaled ¥27,149,529.76, an increase of 65.07% year-on-year, accounting for 1.78% of operating revenue[3] - Research and development expenses for Q1 2022 were ¥27,149,529.76, up from ¥16,447,398.35 in Q1 2021, indicating a focus on innovation[16] Inventory and Receivables - Accounts receivable rose significantly to RMB 685,085,074.84, compared to RMB 342,578,380.56, marking an increase of about 100%[11] - Inventory levels increased to RMB 344,279,186.31 from RMB 250,346,454.01, indicating a rise of approximately 37.5%[12] Other Information - The company reported non-recurring gains of ¥6,311,173.46 for the period[6] - The company has not disclosed any new product or technology developments in this report[11] - There are no significant mergers or acquisitions reported during this period[11] - Total operating costs for Q1 2022 were ¥773,671,474.64, an increase of 93.6% from ¥399,799,615.17 in Q1 2021[16] - The company reported a significant increase in contract liabilities, which rose to RMB 184,179,624.49 from RMB 66,210,879.00, reflecting a growth of about 178%[12]

Financial Performance - The company reported a total revenue of RMB 1.5 billion for the year 2021, representing a year-over-year growth of 20%[11]. - The company's operating revenue for 2021 reached ¥2,839,036,343.41, representing a year-on-year increase of 63.19% compared to ¥1,739,680,701.97 in 2020[23]. - The net profit attributable to shareholders for 2021 was ¥1,193,214,259.45, a 45.59% increase from ¥819,567,339.93 in 2020[23]. - The net profit after deducting non-recurring gains and losses was ¥1,139,627,729.29, reflecting a 45.83% increase from ¥781,455,411.27 in the previous year[23]. - The company's total assets increased by 53.64% to ¥3,499,343,610.85 at the end of 2021, up from ¥2,277,673,271.40 at the end of 2020[23]. - The basic earnings per share for 2021 were ¥20.36, a 45.64% increase compared to ¥13.98 in 2020[24]. - The cash flow from operating activities for 2021 was ¥985,522,925.81, a slight increase of 5.30% from ¥935,881,451.61 in 2020[23]. - The company reported a total revenue of 2,839.04 million RMB in 2021, representing a year-on-year growth of 63.19%[33]. - Revenue from COVID-19 nucleic acid testing reagents reached 1,038.76 million RMB, a 96.06% increase compared to the previous year[34]. - The net profit attributable to shareholders for Q1 was 387.39 million RMB, while Q2 was 114.65 million RMB, Q3 was 494.12 million RMB, and Q4 was 197.06 million RMB[27]. Research and Development - The company invested RMB 200 million in R&D for new technologies, focusing on molecular diagnostics and point-of-care testing solutions[11]. - The company's R&D investment reached 106.64 million yuan, a year-on-year increase of 47.97%, accounting for 3.76% of revenue[36]. - The company has established a cross-disciplinary team of 164 R&D personnel, with 32.93% holding master's degrees or higher[36]. - The company has developed over 600 products utilizing its proprietary core technology platforms, including multiplex fluorescent quantitative PCR, dry chemistry, and automation control[50]. - The company is focusing on high-throughput, closed systems, and timely diagnostics as key technological directions in molecular diagnostics, with NGS and CRISPR technologies being prominent[47]. - The company achieved a prototype completion for home testing instruments, addressing the substantial market demand for home and on-site testing[61]. - The company is accelerating the R&D of upstream core raw materials such as enzymes, antigens, and antibodies to form a complete industry chain from raw materials to instruments and services[111]. Market Expansion and Strategy - The company expects a revenue growth guidance of 25% for the next fiscal year, projecting revenues to reach RMB 1.875 billion[11]. - Market expansion efforts included entering three new international markets, aiming for a 30% increase in international sales[12]. - The company plans to continue its integrated development strategy of "core raw materials + reagents + instruments + services" to promote sustainable growth[35]. - The company is exploring acquisition opportunities in the tech sector, with a budget of $100 million allocated for potential deals[126]. - A new strategic partnership has been established with a leading tech firm to co-develop innovative solutions, expected to launch in Q3 2024[126]. - The company aims to enhance its marketing network by optimizing and integrating distributors and improving direct sales to end customers[114]. Corporate Governance and Compliance - The audit report issued by Lixin Certified Public Accountants is a standard unqualified opinion[4]. - The company has not disclosed any special arrangements for corporate governance[5]. - The company has not faced any situations where more than half of the directors cannot guarantee the authenticity, accuracy, and completeness of the annual report[7]. - The company has established a comprehensive internal governance structure, ensuring effective separation of responsibilities among the shareholders' meeting, board of directors, and supervisory board[161]. - The company has committed to integrating ESG principles into its operations, focusing on environmental protection, social responsibility, and corporate governance[160]. - The company has maintained stable cooperation with suppliers and customers, ensuring mutual benefits and respect for rights[176]. Risk Management - The company has detailed various operational risks and corresponding countermeasures in the report[4]. - The company experienced increased competition in the market, leading to a decrease in profit margins for COVID-19 related products despite revenue growth[25]. - The company faces risks in new product development due to long development cycles of 3-5 years and high R&D failure rates[71]. - There is a risk of core technology leakage, as the company has only patented some key technologies and maintains strict confidentiality measures[71]. - The company anticipates intensified market competition and potential price declines for its reagent products due to regulatory changes and increased market supply[73]. Social Responsibility and Community Engagement - The company actively supported pandemic prevention efforts and contributed to COVID-19 testing initiatives, enhancing its reputation and market presence[34]. - The company donated 2 million RMB and testing reagents to support women's welfare projects and 500,000 RMB to marine education initiatives[172]. - The company has actively participated in social welfare projects, particularly in response to the COVID-19 pandemic, demonstrating its commitment to social responsibility[160]. Employee Relations and Development - The company emphasizes employee training, implementing an annual training plan to enhance overall employee skills and capabilities[150]. - The average salary for R&D personnel decreased to 263,406.10 RMB, down from 328,292.73 RMB in the previous year[67]. - The company has a total of 659,152.25 hours of outsourced labor, with total payments amounting to 15,212,925.50[151]. - The company has established a comprehensive compensation policy that includes project bonuses and performance bonuses to motivate employees[149]. Financial Policies and Shareholder Returns - The company plans to distribute a cash dividend of 100.00 RMB (including tax) for every 10 shares, totaling 586,200,000.00 RMB based on a total share capital of 58,620,000 shares as of December 31, 2021[4]. - The company has a cash dividend policy that stipulates a minimum cash distribution of 10% of the distributable profit if there are no major investment plans or cash expenditures[153]. - The company aims to maintain a stable and continuous profit distribution policy while considering the long-term interests of all shareholders[200]. - The company will prioritize cash dividends when conditions are met, with a preference for cash distribution over stock dividends[200].

2021 年第三季度报告 证券代码：688399 证券简称：硕世生物 江苏硕世生物科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 | | 年初至报 告期末比 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | 年初至报告期末 | 上年同期 | | | | (%) | | 增减变动 | | | | | | 幅度(%) | | 营业收入 | 1,041,310,736.60 | 97.17 | 2,171 ...

Financial Performance - The company reported a total revenue of 1.5 billion RMB for the first half of 2021, representing a year-on-year growth of 25%[1]. - The company reported a revenue of RMB 1.2 billion for the first half of 2021, representing a year-over-year growth of 15%[11]. - The company achieved a revenue of 1,130.56 million RMB in the first half of 2021, representing a growth of 97.46% compared to the same period last year[60]. - Net profit attributable to shareholders was ¥502,032,917.16, up 63.19% compared to the same period last year[20]. - The gross margin for the first half of 2021 was reported at 45%, a slight improvement from 42% in the same period last year[12]. - The company reported a total profit of 8,095,289.16 from various non-operating income sources, with a loss of -175,252.55 from other operating expenses and a tax impact of -1,436,883.15[25]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a 25% growth year-over-year[113]. - The company reported a net profit attributable to shareholders was a loss of ¥322.41 million[179]. User Engagement and Market Expansion - User data indicates an increase in active users by 15%, reaching a total of 2 million users by the end of June 2021[1]. - User data indicates an increase in active users by 20% compared to the previous year, reaching a total of 5 million users[12]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2022[11]. - The company is expanding its market presence, targeting an increase in market share by 10% in the next fiscal year[113]. Research and Development - Research and development expenses increased by 30%, totaling 300 million RMB, reflecting the company's commitment to innovation[1]. - Investment in R&D for new diagnostic technologies increased by 25%, focusing on molecular diagnostics and immunodiagnostics[12]. - R&D investment increased by 39.51% year-on-year, totaling ¥36,678,698.20, driven by an increase in R&D projects and personnel, as well as a significant rise in revenue from COVID-19 testing products[43][44]. - The company’s R&D expenditure as a percentage of operating revenue was 3.24%, a decrease of 1.35 percentage points compared to the previous year[22]. - The company has developed over 400 products in the field of infectious disease detection, establishing itself as a major supplier for nucleic acid testing products in China[31]. - The company is focusing on high-throughput, automated, and time-efficient molecular diagnostic technologies, including NGS and CRISPR[32]. - The company is enhancing its product offerings by integrating automation and smart technologies to improve testing efficiency and accuracy[34]. Product Development and Launches - New product launches are planned, including a next-generation diagnostic tool expected to be released in Q4 2021[1]. - A new line of rapid testing kits is set to launch in Q3 2021, anticipated to contribute an additional RMB 300 million in revenue[12]. - The company has received CE certification for its latest diagnostic products, enabling entry into the European market[11]. - New product development includes the launch of a cutting-edge technology platform expected to generate an additional 300 million yuan in revenue[113]. - The company has developed a series of nucleic acid in vitro diagnostic reagent products based on its multiplex fluorescent quantitative PCR technology platform, including kits for detecting various viruses and pathogens[38]. Financial Management and Governance - The company has no non-operating fund occupation by controlling shareholders or related parties[1]. - There are no violations of decision-making procedures regarding external guarantees[1]. - The board of directors has confirmed that all members attended the board meeting, ensuring governance compliance[1]. - The company has established a commitment to maintain stable operations and control arrangements after the lock-up period[97]. - The company will ensure compliance with the regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange regarding stock transfers[98]. Risks and Challenges - The report emphasizes the importance of risk management strategies in response to potential operational risks[1]. - The company faces risks in new product development, which typically requires 3-5 years from project initiation to registration, with high potential for failure due to various factors[67]. - The company is experiencing increased competition in the in vitro diagnostic reagent industry, which may impact its operational performance and profitability if it cannot maintain its advantages[69]. - The company is at risk of price declines for its reagent products due to regulatory changes and increased competition, which could adversely affect its gross margin and revenue[70]. - The company’s performance has significantly benefited from the COVID-19 pandemic, leading to concerns about the sustainability of this growth in the future[73]. Shareholder and Capital Management - The company did not propose any profit distribution or capital reserve increase during the reporting period[89]. - The company plans to distribute cash dividends of at least 10% of the distributable profits in the next 12 months if there are no major investment plans or cash expenditures[109]. - The company will prioritize cash dividends when conditions are met, with specific conditions including positive distributable profits and sufficient cash flow[110]. - The company commits to ensuring that any changes to the profit distribution policy will prioritize shareholder rights and comply with legal regulations[110]. - The company will actively take legal measures to fulfill all commitments made during the issuance and listing process[101]. Investment and Fundraising - The company has invested a total of RMB 80 million in the Nanjing Weidu Alpha Venture Capital Partnership, increasing its investment from RMB 29 million to RMB 80 million[122]. - Total fundraising amount reached CNY 612,933,570, with CNY 74,311,704.49 invested in the current year[134]. - The Taizhou headquarters project has a total committed investment of CNY 402,650,000, with CNY 58,560,250.84 invested in the current year[134]. - The company has utilized CNY 195,000,000 for cash management from idle fundraising[135]. Legal and Compliance - There were no significant litigation or arbitration matters during the reporting period, indicating a stable legal environment for the company[118]. - The company has established procedures for related party transactions, including board and shareholder approvals when necessary[116]. - The company’s management team is committed to upholding integrity and compliance during their tenure, ensuring accountability[116]. - No significant audit issues were reported for the half-year period, suggesting compliance with auditing standards[118].

2021 年第一季度报告 公司代码：688399 公司简称：硕世生物 江苏硕世生物科技股份有限公司 2021 年第一季度报告 1 / 29 2.1 主要财务数据 非经常性损益项目和金额 √适用 □不适用 3 / 29 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 2,650,255,832.66 2,277,673,271.40 16.36 归属于上市公司股 东的净资产 2,051,883,104.85 1,664,496,808.80 23.27 年初至报告期末 上年初至上年报告期末 比上年同期增减(%) 经营活动产生的现 金流量净额 24,149,786.61 85,282,505.75 -71.68 年初至报告期末 上年初至上年报告期末 比上年同期增减（%） 营业收入 856,511,425.79 200,370,470.59 327.46 归属于上市公司股 东的净利润 387,386,296.05 103,590,955.13 273.96 归属于上市公司股 东的扣除非经常性 损益的净利润 381,777,540.75 94,533,213.87 303.86 ...

Financial Performance - The company reported a total revenue of RMB 1.5 billion for the year 2019, representing a year-over-year growth of 20%[13]. - The company's operating revenue for 2020 reached ¥1,739,680,701.97, representing a 502.39% increase compared to ¥288,794,709.93 in 2019[25]. - Net profit attributable to shareholders increased by 878.52% to ¥819,567,339.93 from ¥83,756,179.76 in the previous year[25]. - The net cash flow from operating activities rose by 776.96% to ¥935,881,451.61, up from ¥106,718,818.92 in 2019[25]. - Basic and diluted earnings per share increased by 655.68% to ¥13.98 from ¥1.85 in 2019[26]. - The weighted average return on equity rose by 39.98 percentage points to 60.06% from 20.08% in the previous year[26]. - Total assets grew by 97.31% to ¥2,277,673,271.40 from ¥1,154,362,463.82 in 2019[25]. - The net assets attributable to shareholders increased by 63.06% to ¥1,664,496,808.80 from ¥1,020,789,468.87 in 2019[25]. - The company's revenue growth was primarily driven by increased demand for COVID-19 testing products due to the pandemic[27]. - In 2020, the company achieved a total revenue of 1,739.68 million RMB, representing a growth of 502.39% compared to the previous year[72]. - The net profit attributable to the parent company reached 819.57 million RMB, an increase of 878.52% year-on-year[72]. Research and Development - Investment in R&D for new diagnostic technologies increased by 30%, focusing on molecular diagnostics and immunodiagnostics[14]. - Total R&D expenditure increased significantly to ¥72,065,668.48, representing an 86.90% growth compared to the previous year[54]. - The company focused on enhancing R&D during the pandemic, which contributed to the substantial increase in R&D investment[55]. - The company has 104 R&D personnel, making up 18.12% of the total workforce, with 50% holding master's degrees or higher[65]. - The company aims to optimize product lines and enhance clinical efficiency through ongoing R&D efforts[57]. - The company is expanding its product offerings to meet the growing market demand for infectious disease testing solutions[57]. - The company plans to enhance its product performance by adopting fluorescence immunoassay technology for disease marker detection[9]. - The company has developed over 500 products, covering infectious disease prevention, clinical testing, large-scale population screening, and reproductive health management[48]. Market Expansion and Strategy - The company expects a revenue growth of 25% for the upcoming fiscal year, driven by new product launches and market expansion strategies[13]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[13]. - The company is actively developing non-COVID products such as HPV and BV testing reagents to mitigate the impact of the pandemic[71]. - The company aims to leverage the "Internet+" opportunity to advance online hospital construction and actively expand into the home-based in vitro diagnostic market[46]. - The company is focusing on increasing the R&D and production scale of core raw materials to capture new profit growth points[81]. - The company plans to enhance its marketing network by optimizing distributor management and expanding direct sales to improve service capabilities[121]. Corporate Governance and Risk Management - The board of directors has confirmed the authenticity and completeness of the annual report, ensuring accountability for any misrepresentation[4]. - The company has outlined various operational risks and corresponding mitigation strategies in the report, emphasizing the importance of risk management[4]. - There are no reported instances of non-operational fund occupation by controlling shareholders or related parties[7]. - The company does not have any special arrangements for corporate governance that would affect the report's integrity[6]. - The company has not violated any decision-making procedures regarding external guarantees[7]. - The company has implemented strict confidentiality measures to protect its core technologies, which are crucial for maintaining competitive advantages[76]. - The company is exposed to macroeconomic risks, particularly regarding the supply of raw materials sourced from overseas amid a complex international trade environment[80]. Shareholder Rights and Profit Distribution - The company plans to distribute cash dividends of at least 40% of profits for mature stages and at least 20% for growth stages when significant capital expenditures are involved[127]. - The company is committed to protecting shareholder rights and will communicate with minority shareholders before profit distribution proposals are reviewed[128]. - The company has a mechanism for adjusting profit distribution policies in response to significant changes in external operating environments or internal conditions[128]. - The company will ensure that any cash dividends distributed will not be less than 30% of the distributable profits for the year[148]. - The company will provide clear explanations for any cash dividend distributions that are lower than expected, including industry characteristics and funding needs[148]. - The company emphasizes the importance of maintaining sufficient cash flow and funding needs when planning dividend distributions[148]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants, indicating a clean financial audit[4]. - The company guarantees that its financial documents for the initial public offering do not contain false statements or omissions, taking legal responsibility for their accuracy[149]. - The company will ensure compliance with regulatory requirements regarding the accuracy of its financial disclosures to protect investor interests[149]. - The company has committed to minimizing related party transactions and ensuring fair pricing in unavoidable cases[162]. Product Development and Innovation - The company has successfully developed a COVID-19 nucleic acid detection reagent in response to the pandemic, significantly increasing production capacity[70]. - The company has launched antigen testing kits for H1N1/H3N2 influenza viruses in the POCT field, generating revenue from these products[142]. - The company has introduced advanced instruments for intelligent and standardized detection of female reproductive tract microecology, improving diagnostic levels in resource-limited areas[142]. - The company is focusing on the integration of diagnostic reagents and instruments, aiming for a fully automated testing process with "sample in, result out" capabilities[143]. Financial Management - The company reported a total of 21,000.00 million RMB in structured deposits as of December 2020, with an annualized return of 3.70%[173]. - The company has ongoing lease agreements with various entities, including a lease amount of 9,000,000 RMB starting from November 13, 2018, to November 12, 2023[166]. - The company has a total of 4,000.00 million RMB in structured deposits with an annualized return of 3.75% as of March 2020[173]. - The total amount of raised funds is CNY 612,933,570, with CNY 67,003,975.53 invested in the current year[179].

Financial Performance - Operating income for the first nine months surged by 477.43% to CNY 1,100,656,632.20[6] - Net profit attributable to shareholders increased by 1,068.91% to CNY 581,793,307.96[6] - Net profit after deducting non-recurring gains and losses increased by 1,060.39% to CNY 553,933,914.61[6] - Basic and diluted earnings per share reached CNY 9.93, up 778.76% compared to the previous year[6] - The company reported a net profit increase of 293.85%, with retained earnings reaching ¥544,075,671.90 compared to ¥138,142,363.94 in the previous year[14] - The net profit for Q3 2020 was CNY 581,793,307.96, representing a 1440.78% increase from CNY 49,772,187.04 in the same period last year, attributed to the surge in COVID-19 product sales[15] - The total profit for Q3 2020 was ¥323.90 million, compared to ¥22.23 million in Q3 2019, reflecting an increase of 1,453.5%[31] Assets and Liabilities - Total assets increased by 62.92% year-on-year, reaching CNY 1,880,702,260.26[6] - The total assets as of September 30, 2020, amounted to CNY 1,435,054,620.07, compared to CNY 890,451,469.04 at the end of 2019, indicating substantial growth in asset base[20] - Total liabilities increased by 239.87% to ¥453,979,483.43 from ¥133,572,994.95, driven by changes in both current and non-current liabilities[14] - Current liabilities rose significantly to ¥361,535,704.90 from ¥94,232,251.97, an increase of approximately 283%[22] - Owner's equity increased to ¥1,426,722,776.83 from ¥1,020,789,468.87, showing a growth of about 39.7%[22] Cash Flow - Net cash flow from operating activities rose by 889.14% to CNY 466,178,480.17[6] - Cash and cash equivalents at the end of Q3 2020 totaled CNY 242,360,125.64, a 914.59% increase from CNY 23,887,396.28 at the end of Q3 2019, driven by improved cash flow from operating activities[16] - The cash flow from operating activities for the first three quarters of 2020 was ¥466,178,480.17, compared to ¥47,129,791.91 in the first three quarters of 2019, indicating a substantial increase[37] - The company reported a cash inflow from operating activities of RMB 1,132,665,834.10 for the first three quarters of 2020, a substantial increase from RMB 205,653,025.32 in the same period of 2019, representing a growth of approximately 450.5%[41] Shareholder Information - The total number of shareholders at the end of the reporting period was 10,496[10] - The top shareholder, Shaoxing RunKang Biological Medicine Equity Investment Partnership, holds 26.61% of shares[10] Research and Development - Research and development expenses increased to CNY 43,842,961.10, up 78.11% from CNY 24,615,181.58 in the previous year, reflecting the company's commitment to enhancing R&D efforts[15] - The company's research and development expenses for the first three quarters of 2020 amounted to ¥44,387,789.20, an increase from ¥25,001,354.52 in the same period of 2019[35] Inventory and Sales - Inventory levels surged by 847.82% to ¥179,886,873.27 from ¥18,978,925.77, primarily due to stockpiling of COVID-19 products[13] - Total revenue from sales of goods and services in Q3 2020 was CNY 1,044,745,780.32, a 451.27% increase from CNY 189,516,938.50 in Q3 2019, mainly due to the rise in sales of COVID-19 products[16] - The company recorded a significant increase in sales expenses, totaling CNY 147,922,753.67, up 129.04% from CNY 64,583,679.59, largely due to increased sales bonuses related to COVID-19 products[15] Government Support - The company received government subsidies, contributing to a 132.26% increase in deferred income to ¥91,127,079.76[14] - The company reported a total of CNY 14,306,543.00 in other income, a 335.77% increase from CNY 3,283,022.51, primarily due to government subsidies received[15] Future Outlook - The company expects a significant increase in net profit for the full year 2020 compared to 2019, although specific growth percentages remain uncertain due to unpredictable factors affecting operations[17]